Loading company…
Mezzion Pharma develops pharmaceutical products, including udenafil for rare and other medical conditions.
Founded in 2002 and based in Seoul, Mezzion Pharma develops drug candidates, including udenafil for conditions such as Fontan-Associated Liver Disease. In June 2025, it raised approximately USD 20 million in venture funding co-led by Midas Asset Management and KDB Capital. The funding will support the Phase 3 FUEL-2 trial of udenafil for people with Fontan circulation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in